Podcast Summary

Podcast: Bloomberg Businessweek
Episode: The Fight Against Alzheimer’s Disease
Date: November 3, 2025
Hosts: Carol Massar and Tim Stenovec
Guest: Dr. Fanny Elahi, Associate Professor of Neurology and Neuroscience, Icahn School of Medicine at Mount Sinai

Episode Overview

This episode of Bloomberg Businessweek focuses on the fight against Alzheimer's Disease, highlighting the higher prevalence in women, emerging scientific hypotheses, the role of hormones and genetics, and promising advances in early detection and treatment. The conversation, led by Carol Massar and Tim Stenovec, centers on Women's Health and features expert insights from Dr. Fanny Elahi.

Key Discussion Points & Insights

1. Women’s Higher Vulnerability to Alzheimer’s Disease

Timestamp: 01:28–03:24

• Statistics: Over 7 million Americans currently have Alzheimer’s, projected to reach nearly 13 million by 2050 (Alzheimer’s Association).
• Prevalence in Women: Alzheimer’s disproportionately affects women, but the reasons are not fully understood.
• Quote (Dr. Elahi at 02:32):

  "One of them is Alzheimer's disease. But to say that it would not be correct to say that we understand the why. And I think this is exactly why we need to be doing research, because getting the answer to why are women's brains more vulnerable... may hold the key to understanding how these diseases strike the vulnerable brain."

Takeaway

Understanding women’s heightened risk could unlock broader insights into neurodegeneration.

2. The Role of Hormones and Menopause

Timestamp: 03:24–05:43

• Central Hypothesis: The drastic hormonal transition during menopause may influence women’s risk. Estrogen loss is unique to women’s mid-life, while in men it occurs later.

• Q&A: Could hormone replacement be the fix?

  • Timing is critical: Hormone therapy must start around perimenopause.
  • Risks: Prolonged use increases risk of certain cancers.
  • Access: Not all women can undergo hormone therapy, so alternative drugs targeting hormone-related pathways are needed.

• Quote (Dr. Elahi at 04:41):

  "You cannot wait too long before starting them... As you alluded to, those hormones also increase the risk of other things, such as cancers, and those risks increase as women age."

Takeaway

While hormone therapy could help, it's a complex tool requiring careful timing and risk assessment, and more targeted treatments are urgently needed.

3. Genetics, Heritability, and Additional Risk Factors

Timestamp: 05:43–06:52

• APOE4 allele: A major genetic risk factor, possibly acting through interaction with hormones.

• Beyond APOE4:

  • Maternal lineage contributes through metabolic and mitochondrial inheritance.
  • Other, yet-unknown aspects of ancestry might influence susceptibility.

• Quote (Dr. Elahi at 05:53):

  "One of the most prevalent genetic risk factors for Alzheimer's disease, the APOE4 allele, we think, interacts with hormones in exerting its effect on Alzheimer's disease."

Takeaway

Genetics, especially when intertwined with hormonal changes, plays a significant but still only partly understood role in disease development.

4. Early Detection—Promise of Blood Biomarkers

Timestamp: 06:52–08:40

• Early is crucial: Blood biomarkers can spot risk decades before symptoms appear, just as in cancer or heart disease.

• State of the field:

  • Current biomarkers detect only a few facets of the disease.
  • No precise biomarkers yet for vascular damage in the brain, a suspected key factor.

• Quote (Dr. Elahi at 07:01):

  "Blood biomarkers are very exciting because similar to other disorders... you really want to detect disease before individuals have prominent symptoms."

• Quote (Dr. Elahi at 08:10):

  "We think a key component of Alzheimer's and other neurodegenerative diseases are the changes that happen to the blood vessels of the brain. And at the moment, we have no biomarkers that detect vascular pathologies with great precision."

Takeaway

Developing accurate blood tests for early detection and vascular changes is a pivotal next step.

5. Optimism for the Future

Timestamp: 08:40–09:07

• Recent Progress: Two FDA-approved drugs now slow disease progression.
• Pipeline: Many innovative therapies in development.
• Quote (Dr. Elahi at 08:49):

  "Absolutely. I'm going to go further in saying that I hope that it's not at the end of my career. I have great hope for the decade that is to come. We already have two FDA approved treatments that slow down disease progression and many other game changing treatments are in the pipeline."

Takeaway

There is tangible progress and justified hope for significant therapeutic breakthroughs within the next decade.

Notable Quotes & Memorable Moments

• On Women’s Higher Risk:
  "Getting the answer to why are women's brains more vulnerable to Alzheimer's disease... may hold the key to understanding how these diseases strike the vulnerable brain." — Dr. Elahi (02:32)
• On Timing of Hormone Therapy:
  "You cannot wait too long before starting them... those hormones also increase the risk of other things, such as cancers..." — Dr. Elahi (04:41)
• On Biomarkers:
  "We think a key component of Alzheimer's... are the changes that happen to the blood vessels of the brain. And at the moment, we have no biomarkers that detect vascular pathologies with great precision." — Dr. Elahi (08:10)
• On the Future:
  "I have great hope for the decade that is to come. We already have two FDA approved treatments... and many other game changing treatments are in the pipeline." — Dr. Elahi (08:49)

Timestamps for Key Segments

• Women’s higher risk & importance of “why” research: 02:32
• Hormonal shifts and perimenopause as risk factor: 03:36–04:41
• Limitations and complexities of hormone therapy: 04:41–05:43
• APOE4 and genetic risk: 05:53
• Promise and limitations of blood biomarkers: 07:01, 08:10
• Hope for future breakthroughs: 08:49

Final Thoughts

This episode succinctly clarifies the intricate interplay of sex, hormonal change, genetics, and early detection in Alzheimer’s Disease, especially for women. With candid, hopeful guidance from Dr. Elahi, listeners gain a clear view of current challenges, ongoing research paths, and the brightening outlook for meaningful progress in both treatment and prevention in the coming years.